Authors: Gesundheit, B Cividalli, G Freeman, A Yatziv, S Koren, G Baruchel, S

Citation: B. Gesundheit et al., Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children, EUR J HAEMA, 66(5), 2001, pp. 347-351

Authors: Stempak, D Dallas, S Klein, J Bendayan, R Koren, G Baruchel, S

Citation: D. Stempak et al., Glutathione stability in whole blood: Effects of various deproteinizing acids, THER DRUG M, 23(5), 2001, pp. 542-549

Authors: Fouladi, M Stempak, D Gammon, J Klein, J Grant, R Greenberg, ML Koren, G Baruchel, S

Citation: M. Fouladi et al., Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma, CANCER, 92(4), 2001, pp. 914-923

Authors: Klement, G Baruchel, S Rak, J Man, S Clark, K Hicklin, DJ Bohlen, P Kerbel, RS

Citation: G. Klement et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J CLIN INV, 105(8), 2000, pp. R15-R24

Authors: Bernstein, ML Baruchel, S Devine, S Markoglou, N Wainer, IW Williams, M Blaney, S Moghrabi, A Winick, N Vietti, T

Citation: Ml. Bernstein et al., Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: A pediatric oncology group study, J PED H ONC, 21(6), 1999, pp. 494-500

Authors: Loebstein, R Atanackovic, G Bishai, R Wolpin, J Khattak, S Hashemi, G Gobrial, M Baruchel, S Ito, S Koren, G

Citation: R. Loebstein et al., Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity inchildren, J CLIN PHAR, 39(5), 1999, pp. 454-461